The information on this website is intended for healthcare
professionals only and is provided for the purpose of scientific exchange.
The website is not country specific and may therefore contain
information that is not applicable in your country, thus you may find
information concerning study drugs or therapeutic uses that have not
been approved by drug regulatory agencies. This website is not
intended to promote in any way, any use, either approved, or
unapproved, of a Novo Nordisk product or of any other product or serve
as basis for any treatment decision or action. Please always refer to
Summary of Product Characteristics (product label) as approved by
regulatory authorities in your country or contact Novo Nordisk for
Furthermore, the site is not intended to replace the advice of a
healthcare professional and should not be construed as providing
advice or making a recommendation. Only a physician can determine
whether a specific product is correct for a particular patient. Novo
Nordisk accepts no liability for the accuracy, completeness or use of
this information, and disclaims any liability to update the
information contained on this site.
By accessing this website you accept this legal notice and expressly
confirm your status as a healthcare professional.
ADA 2021 June 25 - 29
Achievement Of Near-Normal HbA1c With Early Initiation Of Oral Semaglutide: An Exploratory Subgroup Analysis Of PIONEER 1
Vanita R. Aroda1; Lars Bardtrum2; Klaus Kallenbach2; Anne Møller Nielsen2; Julio Rosenstock3; Enrique C. Morales-Villegas4; Melanie Davies5;
1 Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; 2 Novo Nordisk A/S, Søborg, Denmark; 3 Dallas Diabetes Research Center at Medical City, Dallas, TX, USA; 4 Aguascalientes Cardiometabolic Research Center, MAC Hospital, Aguascalientes, Mexico; 5 University Hospitals of Leicester NHS Trust, University of Leicester, and NIHR Leicester Biomedical Research Centre, Leicester, UK;